Abstract
We hypothesized that in individuals with previous SARS-CoV-2 infection, the first vaccine dose would work as a booster, eliciting a faster and more intense immune response. We herein describe antibody responses to the first and second doses of Gam-COVID-Vac (SPUTNIK V) vaccine in health personnel of Tucumán, Argentina, with previous COVID-19 and compared it with uninfected personnel. Individuals with anti-SARS-CoV-2 titers at baseline showed significantly higher responses to the first dose than people with no prior history of disease (p <0.0001), with titers higher to those registered after the second dose in the control group, representing a clear secondary antibody response. This suggests that a single dose of SPUTNIK V for people with previous SARS-CoV-2 infection could contribute to a better use of available doses.
One-Sentence Summary First vaccine dose in subjects with prior COVID19 elicits a higher antibody response than two doses in uninfected individuals
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Ministerio de Salud Publica de Tucuman (REC, RTG, SIC, DP, EVP, MAL, PA, MA, EMdMV, AS, CLA, CMG, SBS, DH, SAN, CLL, DC, IF, GP, RNC) Argentinean Research Council-CONICET grants PIP 722 and 806 (RNC, CMG) Argentinean Research Agency grants MINCYT PICT-2018-3379 and PICT2018-02989 (DP, SBS) Tucuman National University grants (PIUNT-UNT D644/1 and D624 (CLA, CMG) Fundacion Florencio Fiorini (DP)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol used in the present study was opportunely submitted to the: -Comite de Etica en Investigacion- Direccion de Investigacion en Salud- SiProSa (Sistema Provincial de Salud). Address: Virgen de la Merced 189-1st floor- (San Miguel de Tucuman) -4000-Argentine. The protocol was approved by Research Department and Ethics Committee (SiProSa-Tucuman Health Ministery). Identification: Dictamen CEI 29-2020 Contact: +54-9-0381-4526585-ext:120 See all information at: https://msptucuman.gov.ar/wordpress/wp-content/uploads/2021/03/Expediente-N3929-410-P2020-Seroconversin-post-vacunacin-para-SARS-CoV-2-immune-response-after-a-single-vaccine-dose.pdf https://msptucuman.gov.ar/wordpress/wp-content/uploads/2021/03/03.Serocoversion-DICTAMEN-19-1-2021.pdf https://msptucuman.gov.ar/wordpress/wp-content/uploads/2021/03/FCI-SeroconversionRCSfinal.pdf
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
all data are available on demand
